Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
OKYO Pharma Limited Sponsored ADR ( (OKYO) ) has shared an announcement.
On February 10, 2026, OKYO Pharma Ltd entered into a Sales Agreement with Leerink Partners LLC to establish an at-the-market equity program allowing the company to sell up to $50 million of its ordinary shares from time to time on Nasdaq or other U.S. trading venues. The shares will be issued under an effective Form F-3 shelf registration declared effective the same day, with Leerink Partners acting as sales agent or principal, earning a 3% commission on gross sales and having the ability, along with the company, to suspend or terminate sales at any time, providing OKYO with flexible access to incremental equity capital while diluting existing shareholders as new shares are sold.
Under the arrangement, OKYO controls the timing, volume, price floors and daily caps for any sales, and is not obligated to sell any minimum amount of stock, leaving the ultimate size and proceeds of the program undetermined. The agreement includes customary representations, covenants, indemnification provisions and reimbursement of specified expenses for Leerink Partners, positioning OKYO to tap the market opportunistically as funding needs and market conditions dictate without undertaking a single, large equity issuance.
The most recent analyst rating on (OKYO) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock, see the OKYO Stock Forecast page.
Spark’s Take on OKYO Stock
According to Spark, TipRanks’ AI Analyst, OKYO is a Neutral.
The score is held down primarily by weak fundamentals (pre-revenue, ongoing losses, negative free cash flow, and negative equity) despite improved 2025 cost and cash-burn trends and zero debt. Technicals are a meaningful offset with strong momentum above key moving averages, while valuation remains challenged due to negative earnings and no indicated dividend yield.
To see Spark’s full report on OKYO stock, click here.
More about OKYO Pharma Limited Sponsored ADR
OKYO Pharma Ltd is a Guernsey-incorporated biopharmaceutical company whose sponsored ADRs trade on the Nasdaq Capital Market. The company is focused on developing therapies in the healthcare sector, and it raises capital in U.S. markets via registered offerings of its ordinary shares to support its research, development and corporate activities.
Average Trading Volume: 199,861
Technical Sentiment Signal: Sell
Current Market Cap: $72.21M
For an in-depth examination of OKYO stock, go to TipRanks’ Overview page.